Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Cancer Gene Therapy|March 30, 2022
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesotheliomaRihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, et al.
Biochemical Pharmacology|April 25, 2012
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effectsGiuliana Cassinelli, Valentina Zuco, Giovanna Petrangolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2010
Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitineClaudio Pisano, Loredana Vesci, Ferdinando Maria Milazzo, et al.
Disease Models & Mechanisms|May 9, 2023
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograftValentina Zuco, Sandro Pasquali, Monica Tortoreto, et al.
Molecular Cancer Therapeutics|July 23, 2008
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968Claudio Pisano, Michelandrea De Cesare, Giovanni Luca Beretta, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.
Cancer Discovery|February 5, 2024
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination TherapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 2, 2021
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulationValentina Zuco, Sandro Pasquali, Monica Tortoreto, et al.
Bioorganic & Medicinal Chemistry|July 27, 2010
Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitorsLoana Musso, Sabrina Dallavalle, Lucio Merlini, et al.
The Journal of Clinical Investigation|August 12, 2025
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasYaniv Kazansky, Helen S Mueller, Daniel Cameron, et al.
Pageof 7